GRAM-NEGATIVE INFECTIONS: Edited by Matteo BassettiClinical evidence supporting cefiderocol for serious Acinetobacter baumannii infectionsBassetti, Matteoa,b; Vena, Antonioa,b; Castaldo, Nadiac; Giacobbe, Daniele Robertoa,b; Peghin, Maddalenad; Grossi, Paolo Antoniod Author Information aInfectious Diseases Unit, San Martino Policlinico Hospital—IRCCS for Oncology and Neurosciences bDepartment of Health Sciences (DISSAL), University of Genoa cDepartment of Pulmonology, Azienda Sanitaria Universitaria Integrata di Udine, Udine dInfectious and Tropical Diseases Unit, Department of Medicine and Surgery, University of Insubria-ASST-Sette Laghi, Varese, Italy Correspondence to Antonio Vena, Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, Genova, Largo R. Benzi 10, 16132 Genova-, Italy. Tel: +390105554658; e-mail: [email protected]; Matteo Bassetti, Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, Largo R. Benzi 10, 16132 Genova, Italy. Tel: +390105554658; e-mail: [email protected] Current Opinion in Infectious Diseases 35(6):p 545-551, December 2022. | DOI: 10.1097/QCO.0000000000000880 Buy Metrics Abstract Purpose of review Nosocomial infections caused by Acinetobacter baumannii currently represent a serious challenge for clinicians because treatment options are limited and frequently associated with significant toxicity. Cefiderocol is a first-in-class siderophore cephalosporin that has a proven efficacy for the treatment of multidrug-resistant Gram-negative infections, including carbapenem-resistant A. baumannii. The aim of this review is to evaluate the current evidence for the role of cefiderocol in the management of A. baumannii infections. Recent findings In this review, we briefly summarize the available data on the efficacy (from randomized controlled trials) and on effectiveness and cure rates (from observational studies), pertaining to the use of cefiderocol for treatment of serious A. baumannii infections. Summary Cefiderocol represents a promising and safe antibiotic option for treating patients with carbapenem-resistant A. baumannii infections. Due to conflicting mortality data from available experience, well-designed future randomized controlled trials and real-life studies are needed. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.